logo-loader

American Battery Metals appoints tech sector veteran Nick Copping to its Advisory Board

Published: 09:46 01 Apr 2021 EDT

American Battery Metals Corporation -
American Battery Metals said Copping will be instrumental as the company executes on its corporate, environmental, social, and governance initiatives

American Battery Metals Corporation (OTCQB:ABML), which is in the process of changing its name to American Battery Technology Company (ABTC), announced that Nick Copping has joined the company's Advisory Board. 

Copping, who is a Senior Fellow at the Ponemon Institute, is a former senior research director at NASA's Jet Propulsion Laboratory and has previously worked as a director of corporate engineering for Hewlett-Packard. He also co-founded ZOOM Marketing in 1996, after which he became a partner at Microsoft, where he developed the Microsoft Global SI strategy. 

“Nick's professional experience and enthusiasm is a renewable asset unto itself. He will be instrumental as American Battery Metals Corporation continues to grow and execute on our corporate and environmental, social, and governance initiatives,” American Battery Metals Corporation CEO Doug Cole said in a statement.

READ: American Battery Metals achieves notable milestones in the development of its lithium-ion battery recycling pilot plant in Nevada

Copping also commented, stating: “Joining the Advisory board of American Battery Metals Corporation is a unique life mission opportunity.

“In this era of transition to green and renewable energy, American Battery Metals Corporation completes the full cycle of energy resources required to sustain generations to come.”

American Battery Metals is an American-owned lithium-ion battery recycling technology and advanced extraction company with extensive mineral resources in Nevada.

The company is focused on its lithium-ion battery recycling and resource production projects in the state, with the goal of becoming a substantial domestic supplier of battery metals to the rapidly growing electric vehicle and battery storage markets.

Contact Sean at sean@proactiveinvestors.com

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 53 minutes ago